USFDA22 Jan 2026, 05:41 pm
US FDA Concludes Remote Regulatory Assessment of Jeevan Scientific Technology's Clinical Pharmacology Facility
AI Summary
Jeevan Scientific Technology Ltd. has announced the conclusion of a Remote Regulatory Assessment by the United States Food and Drug Administration (US FDA) for studies conducted at their clinical Pharmacology facility in Hyderabad, Telangana, India. The assessment covered the period from 17 October, 2025 to 6 November, 2025. The US FDA has issued a Remote Regulatory Assessment Report based on this review.
Key Highlights
- US FDA concludes Remote Regulatory Assessment of Jeevan Scientific Technology's clinical Pharmacology facility.
- Assessment covers studies conducted from 17 October, 2025 to 6 November, 2025.
- US FDA issues Remote Regulatory Assessment Report based on the review.